The purpose of the ICONIC-ADVANCE 1 study is to help doctors and researchers

learn more about the efficacy of the investigational medication. In this study, doctors want to evaluate the investigational medication when it is compared with a medication that is approved to treat moderate to severe plaque psoriasis, which is known as an active comparator medication. The investigational medication is not approved by any regulatory health authority to treat moderate to severe plaque psoriasis. It is only available to patients like you in research studies like this one.

The results of this study may provide more information about the investigational medication and whether it could one day be used to treat moderate to severe plaque psoriasis.

To qualify for this study, you must:

• Be 18 years of age or older

• Have been diagnosed with moderate to severe plaque psoriasis for at

least 6 months prior to beginning this study

Additional criteria will apply, which you can discuss with the study

doctor/staff.

If you are eligible for this study and agree to participate, you will receive

the investigational medication during your participation. However, initially,

you will be randomly assigned (like drawing numbers out of a hat) to receive

the investigational medication (Group 1), the active comparator medication

(Group 2), or placebo (Group 3). Placebo looks like the investigational

medication but contains no active ingredients.

You have a:

• 2 in 5 chance (40%) of being in Group 1

• 2 in 5 chance (40%) of being in Group 2

• 1 in 5 chance (20%) of being in Group 3

You and the study doctor/staff will not know your study group assignment.

In the event of an emergency, this information can be provided.

You will take your study medication (investigational, active comparator, or

placebo) by mouth once a day.

Group 1

• Weeks 0-156: Takes the investigational medication

Group 2

• Weeks 0-24: Takes the active comparator medication

• Weeks 24-156: Takes the investigational medication

Group 3

• Weeks 0-16: Takes placebo

• Weeks 16-156: Takes the investigational medication

Using placebo helps the study doctor/staff:

• Better understand the effects (good or bad) of the investigational

medication

• Learn if any effects (good or bad) are caused by the investigational

medication

Your total study participation will last approximately 3 years, which

includes screening for eligibility, study medication dosing, and follow-up.

You will have regularly scheduled study clinic visits for health exams and

tests. For the first year, these visits will occur about once a month. As you

continue in the study, these visits will take place once every 2-3 months.

By being in this study, you could help contribute to research for people

with psoriasis in the future. All study-required visits, tests, and medication will be provided at no cost to you. In addition, reimbursement for study-required travel may be provided.

While you could benefit from being in this study, that is not guaranteed. It is also possible you could experience side effects while in this study. Before you begin study participation, the study doctor/staff will review the known study risks and possible side effects with you. During the study, you will be closely monitored for any side effects related to your study participation. The study doctor/staff want you to feel safe and comfortable while you’re in this study.

Yes, if you join the study, you may leave the study at any time and for any reason.